UNSPSC 51181612: Benzylthiouracil

This classification denotes a uridine phosphorylase antagonist and inhibitor with the molecular formula C11H10N2OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PZ35LUM333, chemically known as uracil, benzylthio- but generally known as benzylthiouracil, which bears US NIH Compound Identifier 198125. European Medicines Agency schedules Benzylthiouracil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13040MIG.

World Health Organization schedules benzylthiouracil in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, BENZYLTHIOURACIL remains the US FDA Preferred Term for this commodity. SMILES: C1C=CC=CC1CC23C(=NC=NC2=O)S3.

UNSPSC 51181612 Benzylthiouracil, a Commodity code, encompasses pharmaceuticals and active pharmaceutical ingredients procured by state and local health systems, departments, and cooperative purchasing alliances. Recent state and local activity shows this code being used for multi-source generic pharmaceutical procurement through cooperative vehicles, where issuing bodies source finished pharmaceuticals and over-the-counter products through authorized wholesaler networks rather than direct manufacturer purchases. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) administers the primary recent opportunity in this space, drawing participation from multiple state and local jurisdictions across the country. Vendors responding to such solicitations must maintain current Good Manufacturing Practices (cGMP) certification, comply with Drug Supply Chain Security Act (DSCSA) requirements, and hold contractual relationships with authorized wholesale distributors including AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC. Typical work involves establishing framework agreements with tiered pricing structures (flat price, net price formats, or WAC-minus models), providing comprehensive product data including National Drug Codes (NDC), SKUs, and UPCs, and meeting strict administrative and compliance requirements including substantial insurance coverage ($5 million commercial general liability, $2 million network security and privacy, $2 million professional liability).

The most substantial recent opportunity centers on MMCAP's Request for Proposal (S1070000015802) posted January 20, 2026, with a response deadline of March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products effective July 1, 2026. This cooperative vehicle spans Minnesota, Oregon, and other participating states and local jurisdictions. Evaluation emphasizes price competitiveness (75 percent), with smaller weights on fixed pricing, administrative compliance, EDI capability, and acceptance of the 3 percent administrative fee. Performance penalties of $200 to $1,500 per violation apply for late reporting, missed onboarding deadlines, or improper class-of-trade denials. The contract term is two years for new vendors with optional extensions at MMCAP's discretion, while incumbents' amendments extend through June 30, 2028. No specific award values or budget ranges are disclosed; however, vendors should anticipate the 3 percent administrative fee on all contract purchases.